RNA-seq of human NSCLC cell line treated with Tramatinib or Lorlatinib, at different time points
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/ERP138434
下载链接
链接失效反馈官方服务：
资源简介：
To better understand the differences between different ALK inhibitors on ALK positive NSCLC cell lines, we performed RNA-seq analysis on samples treated with 2 types of ALK inhibitors: Tramatinib and Lorlatinib. Samples taken 6h and 24h after treatment
创建时间：
2024-07-20
